Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers

Cardiovascular Research

Volumn 85, Issue 3, 2010, Pages 444-453

  Jearawiriyapaisarn, Natee ^a,b   Moulton, Hong M ^c   Sazani, Peter ^c   Kole, Ryszard ^a,c   Willis, Monte S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c AVI BIOPHARMA INC   (United States)

Author keywords

Alternative RNA splicing; Cardiomyopathy; Duchenne muscular dystrophy; Exon skipping; Morpholino; Oligomers; Therapy

Indexed keywords

ARGININE; AVI 5225; DYSTROPHIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; GENE MUTATION; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE FIBER MEMBRANE; HEART VENTRICLE HYPERTROPHY; MORBIDITY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

ANIMALS; CARDIOMEGALY; CARDIOMYOPATHIES; DIASTOLE; DYSTROPHIN; GENE THERAPY; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MORPHOLINES; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 74249109987     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp335     Document Type: Article

References (45)

1. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988;2:90-95.
2. Bauman J, Jearawiriyapaisarn N, Kole R. Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides 2009;19:1-14.
3. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M et al. Local dystrophin restoration with antisense oligonucleo-tide PRO051. N Engl J Med 2007;357:2677-2686.
4. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 1998;7:1083-1090.
5. Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using anti-sense oligonucleotides. Neuromuscul Disord 1999;9:330-338.
6. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001;98:42-47.
7. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dys-trophic mouse. Nat Med 2003;9:1009-1014.
8. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005;102:198-203.
9. Gebski BL, Mann CJ, Fletcher S, Wilton SD. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 2003; 12:1801-1811.
10. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD. Dystro-phin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 2006;8:207-216.
11. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006;12:175-177.
12. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP et al. Mor-pholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007;15:1587-1592.
13. Foster K, Foster H, Dickson JG. Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 2006;13:1677-1685.
14. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008;16:1624-1629.
15. Wu RP, Youngblood DS, Hassinger JN, Lovejoy CE, Nelson MH, Iversen PL et al. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 2007;35:5182-5191.
16. Hoffman EP. Skipping toward personalized molecular medicine. N Engl J Med 2007;357:2719-2722.
17. McArdle A, Edwards RH, Jackson MJ. How does dystrophin deficiency lead to muscle degeneration?-evidence from the mdx mouse. Neuromuscul Disord 1995;5:445-456.
18. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuro-muscul Disord 2004;14:491-496.
19. Cohn RD, Liang HY, Shetty R, Abraham T, Wagner KR. Myostatin does not regulate cardiac hypertrophy or fibrosis. Neuromuscul Disord 2007;17:290-296.
20. Buyse GM, Van der Mieren G, Erb M, D'Hooge J, Herijgers P, Verbeken E et al. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J 2008;31:116-124.
21. Markham LW, Michelfelder EC, Border WL, Khoury PR, Spicer RL, Wong BL et al. Abnormalities of diastolic function precede dilated cardiomyopathy associated with Duchenne muscular dystrophy. J Am Soc Echocardiogr 2006;19:865-871.
22. Wilding JR, Schneider JE, Sang AE, Davies KE, Neubauer S, Clarke K. Dystrophin-and MLP-deficient mouse hearts: marked differences in morphology and function, but similar accumulation of cytoskeletal proteins. FASEB J 2005;19:79-81.
23. Pollick C, Hale SL, Kloner RA. Echocardiographic and cardiac Doppler assessment of mice. J Am Soc Echocardiogr 1995;8:602-610.
24. Abes R, Arzumanov AA, Moulton HM, Abes S, Ivanova GD, Iversen PL et al. Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochem Soc Trans 2007;35:775-779.
25. Lebleu B, Moulton HM, Abes R, Ivanova GD, Abes S, Stein DA et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 2008;60:517-529.
26. Townsend D, Yasuda S, Li S, Chamberlain JS, Metzger JM. Emergent dilated car-diomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 2008;16:832-835.
27. Yue Y, Li Z, Harper SQ, Davisson RL, Chamberlain JS, Duan D. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 2003;108: 1626-1632.
28. Denti MA, Rosa A, D'Antona G, Sthandier O, De Angelis FG, Nicoletti C et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci USA 2006;103:3758-3763.
29. Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, Metzger JM. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 2007;15:1086-1092.
30. Bostick B, Yue Y, Lai Y, Long C, Li D, Duan D. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 2008;19:851-856.
31. Denti MA, Incitti T, Sthandier O, Nicoletti C, De Angelis FG, Rizzuto E et al. Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dys-trophic mice. Hum Gene Ther 2008;19:601-608.
32. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Spurney CF et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 2008;105:14814-14819.
33. Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loike JD et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 1988;318:1363-1368.
34. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991;49:54-67.
35. Van der Mieren G, Buyse G, D'hooge J, Herijgers P. Dystrophin deficient MDX mice poorly tolerate dobutamine stress. J Mol Cell Card 2007;42:S164-S165.
36. Connuck DM, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008;155:998-1005.
37. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009;30:293-299.
38. Banks GB, Chamberlain JS. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol 2008;84: 431-453.
39. Tsai KL, Clark LA, Murphy KE. Understanding hereditary diseases using the dog and human as companion model systems. Mamm Genome 2007;18:444-451.
40. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 2008;5: 158-168.
41. Wells DJ. Peptide-conjugated antisense therapy takes a skip ahead. Mol Ther 2008; 16:1523-1524.
42. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyo-pathy in Duchenne muscular dystrophy. Int J Cardiol 1990;26:271-277.
43. Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 2003;99:1-19.
44. Hoogerwaard EM, de Voogt WG, Wilde AA, van der Wouw PA, Bakker E, van Ommen GJ et al. Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. J Neurol 1997;244:657-663.
45. Melacini P, Fanin M, Danieli GA, Fasoli G, Villanova C, Angelini C et al. Cardiac involvement in Becker muscular dystrophy. J Am Coll Cardiol 1993;22:1927-1934.